TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of DirectorsDr. Tendler oversaw 30 Major Drug Approvals, including worldwide approvals for J&J's transformational treatments in hematologic malignancies, prostate, lung and bladder cancers
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of ShareholdersNEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, ML, HURA, KANT on Behalf of ShareholdersNEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipeline
TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" EventLive moderated webcast with Dr. Jim Bianco, President and Chief Executive Officer of TuHURA on Wednesday, October 30th at 4 PM ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of ShareholdersNEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
HURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of TuHURA Biosciences, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of TuHURA Biosciences, Inc. (
NASDAQ: HURA) and Kineta, Inc. is fair to TuHURA shareholders.
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business UpdateIFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC) under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA)
